Article citationsMore>>

Di Bisceglie, A.M., Conjeevaram, H.S., Fried, M.W., Sallie, R., Park, Y., Yurdaydin, C., et al. (1995) Ribavirin as Therapy for Chronic Hepatitis C: A Randomized, Double-Blind, Placebo-Controlled Trial. Annals of Internal Medicine, 123, 897-903.
http://annals.org/article.aspx?articleid=709279

has been cited by the following article:

• TITLE: The Antiviral Efficacy of Withania somnifera (Ashwagandha) against Hepatitis C Virus Activity: In Vitro and in Silico Study

  AUTHORS: Dina Mofed, Wafaa Ahmed, Abdel-Rahman Zekri, Ola Said, Mohamed Rahouma, Ahmed Hassan Ibrahim Faraag

  KEYWORDS: Antiviral, Ashwagandha, Hepatitis C Virus, Docking, Lymphocyte

  JOURNAL NAME: Advances in Microbiology, Vol.10 No.9, September 27, 2020

  ABSTRACT: Objective: Evaluation antiviral effects of Withania somnifera (Ashwagandha) leaf extract against HCV. Methods: cell proliferation was assessed using MTT assay after isolation of lymphocyte cells and treated with Ashwagandha water extract (ASH-WX) (6.25 mg/ml - 100 mg/ml). Assessment of quantitative Real-time PCR, Colony forming assay, TNF-α and molecular docking studies after infection of normal lymphocyte cells with 1 ml (1.5 × 106 HCV) serum then incubated with ASH-WX at concentration 25 mg/ml & 50 mg/ml. Results: MTT assay revealed a significant increase (p α significantly decreased following ASH-WX treatment compared with control untreated infected cells (p 3 IU/mL. Colony formation assay test revealed colony formation reduction compared to positive untreated control. Molecular docking analysis revealed good prediction of binding between Ashwagandha and NS5B and PKN2 compared to Sovaldi. Conclusion: ASH-WX may be a powerful antiviral against HCV infection.